EGFR and lung cancer: In 2019, Creelan and colleagues conducted a Phase I clinical trial testing the combination of dasatinib and afatinib on 25 lung cancer patients with activating mutations on EGFR exon 19 or 21 or disease progression following prior EGFR-TKI therapy (Table 2; [95]).